Joana Roseira

Joana Roseira

Auto-generated profile, based on publicly available information

Joana Roseira

Department of Gastroenterology, Portimão Hospital, Unidade Local de Saúde do Algarve , Portimão

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2020 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
JRJoana Roseira
Joana Roseira
AVAna Rita Ventosa
Ana Rita Ventosa
HSHelena Tavares de Sousa
Helena Tavares de Sousa
JBJorge Brito
Jorge Brito
Background: A simplified magnetic resonance enterography (MRe) index (sMARIA) for Crohn’s disease (CD) was recently developed and validated.Objective: Our aims were (a) to assess sMARIA’s accuracy in a sample other than the validation cohort; (b) to evaluate its correlation with a simpler endoscopy index (SES‐CD) and fecal calprotectin (FC); and (c) to assess the need of an expert radiologist to reliably use sMARIA.Methods: Patients with CD who underwent MRe, ileocolonoscopy and FC within 2–4 weeks had their MRe retrospectively reviewed by two blinded raters. Disease activity was evaluated through sMARIA, SES‐CD and FC. sMARIA’s accuracy, indices correlation, and interrater reliability were assessed.Results: In total, 84 patients were included, comprising 420 intestinal segments evaluations. sMARIA ≥1 accurately identified segments with active disease (90% sensitivity, 98% specificity; area under the curve 0.94, 95% confidence interval (CI) 0.91–0.97; p < 0.01). sMARIA correlated with endoscopy, both for ileal and colonic segments (R = 0.94 and R = 0.82; p < 0.01). Per patient, there was a strong correlation between sMARIA, endoscopy (R = 0.95; p < 0.01) and FC (R = 0.91; p < 0.01). Interrater agreement was excellent (intraclass correlation coefficient 0.95; 95% CI 0.94–0.96; p < 0.01).Conclusion: sMARIA accurately measured CD activity using SES‐CD as standard of reference, and exhibited high correlation with a simple endoscopic index and a biomarker. The interrater reliability between a radiology resident and an expert was excellent.

19 August 2022 in Gut
Verified
Journal Article
Closed access
PDF file
JNJoão A Cunha Neves
João A Cunha Neves
JRJoana Roseira
Joana Roseira
PQPatrícia Queirós
Patrícia Queirós
HSHelena Tavares de Sousa
Helena Tavares de Sousa
Gianluca PellinoGianluca Pellino
Gianluca Pellino
MCMiguel F Cunha
Miguel F Cunha
Objective: Endoscopy is healthcare’s third largest generator of medical waste in hospitals. This prospective study aimed to measure a single unit’s waste carbon footprint and perform a pioneer intervention towards a more sustainable endoscopy practice. The relation of regulated medical waste (RMW; material fully contaminated with blood or body fluids or containing infectious agents) versus landfill waste (non-recyclable material not fully contaminated) may play a critical role. Design: In a four-stage prospective study, following a 4-week observational audit with daily weighing of both waste types (stage 1), stage 2 consisted of a 1-week intervention with team education of waste handling. Recycling bins were placed in endoscopy rooms, landfill and RMW bins were relocated. During stages 3 (1 month after intervention) and 4 (4 months after intervention), daily endoscopic waste was weighed. Equivalence of 1 kg of landfill waste to 1 kg carbon dioxide equivalent (CO 2e ) and 1 kg of RMW to 3kgCO 2e was assumed. Paired samples t-tests for comparisons. Results: From stage 1 to stage 3, mean total waste and RMW were reduced by 12.9% (p=0.155) and 41.4% (p=0.010), respectively, whereas landfill (p=0.059) and recycling waste increased (paper: p=0.001; plastic: p=0.007). While mean endoscopy load was similar (46.2 vs 44.5, p=0.275), a total decrease of CO 2e by 31.6% (138.8kgCO 2e ) was found (mean kgCO 2e 109.7 vs 74.9, p=0.018). The annual reduction was calculated at 1665.6kgCO 2e . All these effects were sustained 4 months after the intervention (stage 4) without objections by responsible endoscopy personnel. Conclusion: In this interventional study, applying sustainability measures to a real-world scenario, RMW reduction and daily recycling were achieved and sustained over time, without compromising endoscopy productivity.

27 August 2019 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
JRJoana Roseira
Joana Roseira
Fernando MagroFernando Magro
Fernando Magro
SFSamuel Fernandes
Samuel Fernandes
CSCarolina Simões
Carolina Simões
FPFrancisco Portela
Francisco Portela
HSHelena Tavares de Sousa
Helena Tavares de Sousa
The impact of inflammatory bowel disease (IBD) on sexual health is a leading concern among patients. Most studies focus on sexual dysfunction rather than patient-perceived sexual quality of life (SQoL). We aimed to assess SQoL in IBD patients compared with healthy controls. This is a multicenter, cross-sectional study of IBD patients (n = 575 with Crohn’s disease and n = 294 with ulcerative colitis), compared with healthy controls (n = 398), that used an anonymous self-administered questionnaire. This multimodal questionnaire included sociodemographic data and 4 validated instruments: Short IBD Questionnaire, Social Desirability Scale, Sexual QoL Questionnaire–Male/Female, Nine-item Patient Health Questionnaire. Inflammatory bowel disease patients reported lower SQoL (men: 77.29 vs 83.83; P < 0.001; women: 70.40 vs 81.63; P < 0.001) compared with controls. Among IBD patients, SQoL was positively correlated with health-related quality of life (HRQoL) and negatively correlated with depression symptoms. Perianal disease was associated with lower HRQoL and higher incidence of depression, but only impacted SQoL in men. In linear regression analysis for men, SQoL was associated with age, marital status, and depression (β, –2.101; 95% confidence interval [CI], –2.505 to –1.696; P < 0.001). In women, SQoL was associated with depression (β, –1.973; 95% CI, –2.313 to –1.632; P < 0.001) only. Patients with IBD had impaired SQoL compared with healthy controls. Age, widow status, and depression were independent predictors of SQoL in men with IBD, whereas in women depression was the only independent predictor. Emotional and self-esteem issues were the main concerns reported by IBD patients regarding sexual health.

1 January 2023 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
AKAditi Kumar
Aditi Kumar
NYNuha Yassin
Nuha Yassin
AMAlexandra Marley
Alexandra Marley
VBVittoria Bellato
Vittoria Bellato
CFCaterina Foppa
Caterina Foppa
MBMatthew J. Brookes
Matthew J. Brookes
An estimated 2.5–3 million individuals (0.4%) in Europe are affected by inflammatory bowel disease (IBD). Whilst incidence rates for IBD are stabilising across Europe, the prevalence is rising and subsequently resulting in a significant cost to the healthcare system of an estimated 4.6–5.6 billion euros per year. Hospitalisation and surgical resection rates are generally on a downward trend, which is contrary to the rising cost of novel medication. This signifies a large part of healthcare cost and burden. Despite publicly funded healthcare systems in most European countries, there is still wide variation in how patients receive and/or pay for biologic medication. This review will provide an overview and discuss the different healthcare systems within Western Europe and the barriers that affect overall management of a changing IBD landscape, including differences to hospitalisation and surgical rates, access to medication and clinical trial participation and recruitment. This review will also discuss the importance of standardising IBD management to attain high-quality care for all patients with IBD.

6 March 2023 in United European Gastroenterology Journal
Verified
Journal Article
Open access
Fernando MagroFernando Magro
Fernando Magro
PMPaula Leão Moreira
Paula Leão Moreira
GCGaia Catalano
Gaia Catalano
CACatarina Alves
Catarina Alves
JRJoana Roseira
Joana Roseira
MSMafalda Santiago
Mafalda Santiago
Background and Aims: The availability of biological agents for inflammatory bowel disease has increased over the past years. In this systematic review and meta‐analysis, we aimed to explore time trends in clinical response and clinical remission rates in Crohn's disease (CD) patients treated with biologics while discussing the need for new strategies.Methods: MEDLINE, Cochrane, and ISI Web of Science databases were searched for randomized placebo‐controlled trials with biological agents in moderate‐to‐severe CD patients. Sub‐group and meta‐regression analyses compared treatment and placebo by calculating the pooled odds ratios of clinical remission and clinical response, across time categories and publication year. We also estimated the proportion of patients achieving clinical remission and clinical response by comparing both groups according to the publication year.Results: Twenty‐five trials were included in the systematic review, which enrolled 8879 patients between 1997 and 2022. The clinical remission and clinical response odds, in induction and maintenance, have been constant over time, as no statistically significant differences were found between time categories (interaction p‐values: clinical remission [induction, p = 0.19; maintenance, p = 0.24]; clinical response [induction, p = 0.43; maintenance, p = 0.59]). In meta‐regression analyses, publication year did not influence these outcomes (clinical remission [induction, OR 1.01{95% CI 0.97–1.05}, p = 0.72; clinical response [induction, OR 1.01{95% CI 0.97–1.04]; p = 0.63; maintenance, OR 1.03{95% CI 0.98–1.07}; p = 0.21]), with the exception of clinical remission in maintenance studies, which presented a decreased effect (odds ratio 0.97{95% CI 0.94–1.00}, p = 0.03]).Conclusions: Our review highlights that the odds of clinical outcomes in CD patients receiving biological treatment relative to placebo have been stable in the last decades.

1 September 2022 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
Fernando MagroFernando Magro
Fernando Magro
DMDiogo Magalhães
Diogo Magalhães
MPMarta Patita
Marta Patita
BABruno Arroja
Bruno Arroja
PLPaula Lago
Paula Lago
CDClaudia Camila Dias
Claudia Camila Dias